Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational ...

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program ...

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market ...

Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expect ...

Discover 25 top investment-grade stocks to buy! See strategies to capitalize on market volatility and build a portfolio to ...

NKTR fourth-quarter earnings and revenues lag estimates. 2025 is poised to be a catalyst year for rezpeg, with multiple data readouts expected. Stock rises.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased ...